Top 10 Healthcare EHR Software in France for 2026

Epic Systems is the enterprise hospital EHR market leader, founded 1979 by Judy Faulkner in Verona, Wisconsin. Privately-held, founder-led for 45 years (Faulkner still CEO). Epic holds approximately 31% US hospital market share (KLAS data) and dominates the academic medical center segment (~80%+ of teaching hospitals). The platform centers on integrated clinical + revenue cycle + patient portal + analytics across hospital + ambulatory + post-acute settings. Strengths: deepest clinical workflow depth in category, mature interoperability via Care Everywhere (Epic-to-Epic) + Carequality (cross-vendor), industry-leading EHR certification, strong physician satisfaction in implementations (when done right), private founder-led culture (no PE pressure pattern), and aggressive AI feature velocity (Epic Cosmos for population health AI, Microsoft DAX Copilot integration for ambient clinical documentation). Best fit for $1B+ revenue health systems, academic medical centers, and large hospital networks. Trade-offs: pricing meaningful ($10M-$500M+ multi-year contracts typical), implementation complex (18-36 months for large health systems), high training burden for clinicians, customization requires Epic-employed implementation consultants, and post-implementation cost of optimization continues for years.

Cerner (rebranded Oracle Health in 2022) is the second-largest US hospital EHR vendor. Founded 1979 in Kansas City. Oracle acquired Cerner December 2021 for $28.3B in cash, the largest healthcare IT acquisition ever, completed June 2022. Strengths: deep enterprise hospital EHR feature set, Oracle financial capacity for AI investment, strong VA Health implementation experience (US Department of Veterans Affairs $16B contract), mature population health module. Best fit for existing Cerner hospital customers and Oracle-anchored health systems. Trade-offs: post-Oracle acquisition integration has been rocky, multiple major hospital systems migrated from Cerner to Epic 2023-2024 (Geisinger, Sentara, multiple academic centers); Oracle leadership churn affected the Cerner team substantially; VA Health Oracle implementation has been troubled with reports of patient harm prompting Congressional hearings; pricing escalations reported under Oracle ownership. The honest editorial read: Cerner remains a credible enterprise EHR but Oracle has not yet demonstrated it can stabilize the customer base. Buyers evaluating between Epic and Cerner in 2026 face a strategic question about Oracle commitment.

athenahealth is the ambulatory practice EHR + revenue cycle management market leader, founded 1997. Public NASDAQ:ATHN 2007-2019, then PE-acquired by Veritas Capital 2019, then re-acquired by Bain Capital + Hellman & Friedman in February 2022 at $17B, one of the largest PE healthcare-software transactions. The platform centers on cloud-based ambulatory EHR + RCM (revenue cycle management) + patient engagement combined. Strengths: best-in-class ambulatory RCM, cloud-first architecture (rare in healthcare IT), broad ambulatory installed base, mature interoperability, and athenaIDX (AI-driven workflow). Best fit for physician group practices (10-500 physicians) and ambulatory clinics. Trade-offs: Bain + Hellman & Friedman PE pressure pattern (typical 5-year hold; pricing escalations reported), implementation 3-9 months, customer support quality variable post-2022 take-private, less suited for hospital + inpatient scope (Epic better), and revenue-share pricing model on RCM creates principal-agent tension.

NextGen Healthcare is the long-running ambulatory EHR platform, founded 1998. Public NASDAQ:NXGN 2008-2024. Thoma Bravo announced take-private acquisition August 2024, completed November 2024 at $1.8B ($23.95/share). The platform centers on ambulatory EHR + practice management + revenue cycle for mid-market physician groups. Strengths: mid-market ambulatory sweet spot, mature 25-year track record, broad specialty support (cardiology, orthopedics, primary care), strong revenue cycle integration, and Thoma Bravo capital for AI investment. Best fit for mid-market physician groups (25-500 physicians) wanting NextGen-anchored ambulatory workflow. Trade-offs: Thoma Bravo PE pressure pattern (pricing escalations typical 6-18 months post-take-private), implementation 4-12 months, customer support quality variable, AI features below Epic/athenahealth on velocity, and recently-private creates roadmap uncertainty.

eClinicalWorks is the privately-held ambulatory EHR + revenue cycle platform, founded 1999. Founder-led for 25 years. The platform centers on ambulatory practice management + EHR + RCM + telehealth for small-to-mid practices. Strengths: founder-led 25 years (no PE pressure), broad ambulatory installed base (130K+ providers), aggressive AI feature velocity (eClinicalWorks 2024 launched Sunoh.ai for AI scribe + eCW Cardiology AI), and competitive pricing. Best fit for ambulatory practices (5-200 physicians) wanting modern AI features at competitive pricing. Trade-offs: MUST flag the 2017 DOJ $155M settlement over EHR certification fraud where eClinicalWorks falsely claimed compliance with ONC EHR certification standards while collecting Medicare Meaningful Use incentive payments, this is a foundational trust event in the company history that buyers should factor; subsequent operational improvements have been documented but the underlying trust gap remains for some buyers. Customer support quality variable, implementation 2-6 months typical, and product velocity faster than legacy peers but UX feels denser than athenahealth.

Veradigm (formerly Allscripts Healthcare Solutions) is the long-running ambulatory EHR + payer/life-sciences data platform, founded 1986. Allscripts was public NASDAQ:MDRX 1999-2024; rebranded to Veradigm in January 2022; was delisted from NASDAQ in September 2024 after multiple accounting restatements and missed SEC filing deadlines. The platform spans Veradigm EHR + practice management + payer + life sciences data businesses. Strengths: long-running 40-year track record, broad payer + life sciences data assets, multiple specialty EHRs in portfolio, and existing customer installed base. Best fit for existing Veradigm customers on legacy Allscripts/TouchWorks/Sunrise platforms. Trade-offs: MAJOR vendor stability concerns, multiple accounting restatements 2023-2024 prompted NASDAQ delisting Sept 2024; SEC investigations active; uncertain corporate trajectory; AI features below competitors; customer support quality has degraded substantially through the financial turmoil; many customers actively migrating to other EHRs. The honest editorial read: Veradigm faces existential vendor-stability questions in 2026 that buyers must factor into multi-year contract decisions.

DrChrono is the modern iPad-first ambulatory EHR for small practices, founded 2009 in YC W11. Acquired by EverHealth (formerly Practice Mate parent) in 2021. The platform pioneered iPad-first clinical documentation and remains the strongest iPad EHR. Strengths: best-in-class iPad-first UX, modern California engineering, strong fit for solo + small specialty practices (5-50 physicians), competitive SMB pricing, and YC W11 legacy momentum. Best fit for solo practices and small specialty groups wanting modern iPad-first workflow. Trade-offs: EverHealth ownership integration ongoing, brand recognition declined post-acquisition, AI features below eClinicalWorks Sunoh.ai, less suited for mid-market multi-specialty groups, and customer support quality variable post-acquisition.

Tebra is the SMB practice management + EHR + patient engagement platform formed from the November 2022 merger of Kareo (founded 2004) and PatientPop (founded 2014). PE-backed by Vista Equity Partners (continuing from Kareo). The platform bundles cloud-based EHR + practice management + patient engagement + reputation management for small practices. Strengths: bundled platform reduces vendor sprawl, modern California engineering, SMB-friendly pricing, mature 20-year Kareo track record, and PatientPop reputation management differentiator. Best fit for SMB practices (1-50 physicians) wanting bundled practice management + EHR + patient engagement. Trade-offs: post-merger integration ongoing 2022-2026; Vista Equity PE pressure pattern; clinical EHR depth below athenahealth/eClinicalWorks; customer support quality variable post-merger; AI features below leaders.

Greenway Health is the mid-market ambulatory EHR + practice management platform, founded 1979. Vista Equity Partners PE-backed since 2013 (12+ year hold, longer than typical PE cycle). The platform centers on mid-market ambulatory practices with Intergy + Prime Suite legacy products. Strengths: mature 45-year track record, strong fit for mid-market ambulatory practices, broad specialty support, established revenue cycle, and Vista Equity capital. Best fit for mid-market ambulatory practices (20-200 physicians) wanting alternative to NextGen/athenahealth. Trade-offs: Vista Equity 12+ year hold is unusual (typically PE 5-7 year hold) and creates uncertainty about exit timing; pricing escalations reported under Vista; multiple product lines (Intergy + Prime Suite + Greenway Carequality) create platform fragmentation; AI features below Epic/athenahealth/eClinicalWorks; customer support quality variable, and innovation pace below modern competitors.

Practice Fusion is the originally-free ambulatory EHR, founded 2005 in San Francisco. Pioneered the "free EHR" model with advertising revenue but discontinued the free tier in 2018. Acquired by Allscripts (now Veradigm) in February 2018 for $100M. The platform centers on lightweight ambulatory EHR for solo and small specialty practices. Strengths: lightweight modern UX (inherited from free-EHR era), strong fit for solo practices, low entry pricing, and broad installed base from free-tier years. Best fit for solo practices and very small specialty groups (1-5 physicians) wanting lightweight EHR. Trade-offs: Veradigm/Allscripts parent has MAJOR vendor stability concerns (NASDAQ delisted Sept 2024, accounting restatements, SEC investigations, see Veradigm entry for details); customers may face uncertain vendor trajectory; AI features below modern competitors; customer support quality degraded with Veradigm financial turmoil; less suited for mid-market practices.